This study is in progress, not accepting new patients

Continuing Access To AG- 013736 (A406) For Patients Previously Receiving AG 013736 In Clinical Trials

Charles Ryan

Description

To allow continuation of treatment of patients experiencing benefit from AG 013736

Continuing Access To The Tyrosine Kinase Inhibitor Of Vegfr 2, Ag 013736 (a406) For Patients Previously Receiving Ag 013736 In Clinical Trials

Solid Tumors VEGFR inhibitor angi-angiogenic tyrosine kinase inhibitor Axitinib

Patients who were assigned to an axitinib containing treatment arm in a previous clinical trial
Patients who were receiving axitinib tablets at the time their previous trial ended
Patients who have stable (SD) or responding disease (PR or CR) documented by the appropriate radiological, clinical, or laboratory assessments within 12 weeks before enrollment (Note: response criteria from the previous AG-013736 protocol should be used to determine stable or responding disease).
Patients who have progressive disease (PD) but have experienced "clinical benefit" as defined in the study protocol

Patients may not participate in this trial if the conditions for continuing treatment in the previous AG-013736 protocol are not met

UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, 94158, United States
UCLA Hematology-Oncology-Santa Monica
Santa Monica, California, 90404, United States
UC Irvine Medical Center
Orange, California, 92868, United States
University of California Irvine Medical Center - Chao Family Comprehensive Cancer Center
Orange, California, 92868, United States

Status: in progress, not accepting new patients
Start Date: March 2003
Completion Date: May 2021 (estimated)
Sponsor: Pfizer
Links: To obtain contact information for a study center near you, click here.
ID: NCT00828919
Lead Scientist: Charles Ryan
Study Type: Interventional
Last Updated: April 10, 2018